Display options
Cite
Pérez Velasco R. Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. Pharm Pract (Granada). 2010;8(4):213-9doi: 10.4321/s1886-36552010000400002.
Pérez Velasco, R. (2010). Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. Pharmacy practice, 8(4), 213-9. https://doi.org/10.4321/s1886-36552010000400002
Pérez Velasco, Román. "Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience." Pharmacy practice vol. 8,4 (2010): 213-9. doi: https://doi.org/10.4321/s1886-36552010000400002
Pérez Velasco R. Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. Pharm Pract (Granada). 2010 Oct;8(4):213-9. doi: 10.4321/s1886-36552010000400002. PMID: 25126143; PMCID: PMC4127058.
Copy Download .nbib Format: NLM
Share it on

Pharm Pract (Granada). 2010 Oct;8(4):213-9. doi: 10.4321/s1886-36552010000400002.

Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience.

Pharmacy practice

Román Pérez Velasco

Affiliations

  1. Research Assistant, Health Intervention and Technology Assessment Program. Department of Health, Ministry of Public Health. Nonthaburi ( Thailand ).

PMID: 25126143 PMCID: PMC4127058 DOI: 10.4321/s1886-36552010000400002

Abstract

UNLABELLED: Granulocyte colony-stimulating factors (G-CSF) are high-cost agents recommended as prophylaxis of febrile neutropenia or as adjunctive treatment of severe neutropenic sepsis. Their use in high-risk situations such as acute myeloid leukaemia, acute lymphocytic leukaemia, myelodysplastic syndrome and stem cell transplantation is also indicated.

OBJECTIVE: This audit assessed the use of G-CSF within the Oncology and Haematology Service Delivery Unit at Guy's and St. Thomas' hospital (London, United Kingdom).

METHODS: Patients who received G-CSF in April-May 2008 were identified retrospectively from the pharmacy labelling system, and chemotherapy front sheets, clinic letters and transplantation protocols were reviewed. Patients on lenograstim, in clinical trials or under non-approved chemotherapy protocols were excluded.

RESULTS: A total of 104 G-CSF treatments were assessed. The most commonly treated malignancy was breast cancer (41.3%), with docetaxel 100 mg/m (2) (34.6%) being the most frequent chemotherapy regimen. The chemotherapy intent was curative in 66.3 % of cases. Pegfilgrastim was used in 73.1 % of cases and primary prophylaxis was the most common indication (54.8%). Stem cell transplantation was the first indication to meet the audit criterion (93.3%), followed by primary prophylaxis (89.5%). There was a considerable nonadherence for secondary prophylaxis (6.7%).

CONCLUSION: The overall level of compliance with the audit criteria was 72.1%. The results for primary and secondary prophylaxis would have been different if FEC100 (fluorouracil, epirubicin, cyclophosphamide) and docetaxel 100 mg/m (2) had been considered a single chemotherapy regimen. Also, the lack of access to medical notes may have affected the reliability of the results for 'therapeutic' use.

Keywords: Clinical Audit; Drug Utilization Review; Hematopoietic Cell Growth Factors; Neutropenia; United Kingdom

References

  1. J Clin Oncol. 2006 Jul 1;24(19):3187-205 - PubMed
  2. J Clin Oncol. 1999 Dec;17(12):3835-49 - PubMed
  3. Ann Pharmacother. 2000 Jul-Aug;34(7-8):851-7 - PubMed
  4. Eur J Cancer. 2006 Oct;42(15):2433-53 - PubMed
  5. J Clin Oncol. 2005 Jun 20;23(18):4198-214 - PubMed
  6. J Clin Oncol. 2006 Dec 20;24(36):5664-71 - PubMed

Publication Types